Oasmia Pharmaceutical AB
Interim report for the period May – October 2014
DGAP-News: Oasmia Pharmaceutical AB 04.12.2014 / 08:15 --------------------------------------------------------------------- Postitive risk/benefit profile in Paclical study Uppsala, Sweden, 2014-12-04 08:15 CET (GLOBE NEWSWIRE) -- SECOND QUARTER August 1 - October 31, 2014 -- Consolidated Net sales amounted to TSEK 558 (24)[1] -- Operating income amounted to TSEK -24,145 (-17,374) -- Net income after tax amounted to TSEK -26,715 (-18,661) -- Earnings per share amounted to SEK -0.30 (-0.23) -- Comprehensive income amounted to TSEK -26,715 (-18,661) THE PERIOD May 1 - October 31, 2014 -- Consolidated Net sales amounted to TSEK 1,552 (24) -- Operating income amounted to TSEK -54,496 (-34,359) -- Net income after tax amounted to TSEK -59,704 (-36,885) -- Earnings per share amounted to SEK -0.69 (-0.45) -- Comprehensive income amounted to TSEK -59,704 (-36,885) -- The full report from the clinical trial with Oasmia's product Paclical for treatment of ovarian cancer shows that Paclical has a positive risk/benefit profile compared to standard treatment. -- Anders Blom was appointed Executive Vice President in Oasmia, succeeding Hans Sundin who was elected as a new member of the Board. EVENTS AFTER THE CLOSING DAY -- On November 11, Oasmia announced a fully committed and underwritten rights issue of approximately SEK 176 million. -- On November 17, Oasmia published the prospectus for the rights issue. CEO COMMENTS: 'Oasmia has had a very successful year so far, and we have achieved a number of important milestones, including the launch in the US of our first veterinary product Paccal Vet-CA1(R). This quarter, we were able to announce the full results from our pivotal Phase III clinical study of Paclical, for the treatment of ovarian cancer. The results showed, among other things, that Paclical has a positive risk/benefit profile compared to the standard treatment, and that the benefits exceed the risks. The results will provide a basis for a Marketing Authorisation Application in Europe to the European Medicines Agency (EMA) in 2015.', commented Julian Aleksov, CEO and President of Oasmia [1] The numbers in parentheses show the results from the corresponding period of the previous year Anders Lundin, CFO Tel: +46 70 209 63 00 E-post: anders.lundin@oasmia.com News Source: NASDAQ OMX --------------------------------------------------------------------- 04.12.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Oasmia Pharmaceutical AB Sweden ISIN: SE0000722365 End of News DGAP News-Service --------------------------------------------------------------------- 302277 04.12.2014
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden